Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. BOOSTAGEN SUSPENSION FOR INJECTION [SIN16493P]

BOOSTAGEN SUSPENSION FOR INJECTION [SIN16493P]

Active ingredients: BOOSTAGEN SUSPENSION FOR INJECTION

Last updated 26 October 2025

Product Info

BOOSTAGEN SUSPENSION FOR INJECTION

[SIN16493P]

Product information

Active Ingredient and Strength

DIPHTHERIA TOXOID (DT) - 2 LF/0.5 ML
FILAMENTOUS HAEMAGGLUTININ (FHA) - 5 MCG/0.5 ML
RECOMBINANT PERTUSSIS TOXIN (RPT) - 5 MCG/0.5 ML
TETANUS TOXOID (TT) - 7.5 LF/0.5 ML

Dosage Form

INJECTION, SUSPENSION

Manufacturer and Country

BIONET-ASIA CO., LTD - THAILAND

Registration Number

SIN16493P

Licence Holder

NOVEM HEALTHCARE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J07AJ52

INDICATION
Boostagen® is indicated for:

  • active booster immunization against tetanus, diphtheria and pertussis in individuals from the age of 3 years onwards.

  • maternal immunization in pregnant women for the prevention of pertussis in infants too young to be vaccinated.

Boostagen® is not indicated for primary immunization.

POSOLOGY
A single 0.5 mL dose of Boostagen® is recommended. Boostagen® should be given in accordance with WHO and national recommendations or medical practices for booster vaccination and for maternal immunization in the second or third trimester preferably at least 15 days before the end of pregnancy, for protection of infants against pertussis.
Boostagen® can be used for tetanus prophylaxis in wound management. Tetanus immunoglobulin should be administered in accordance with existing recommendations.

CONTRAINDICATION
Boostagen® should not be administered to individuals with past experience or signs of:

  • hypersensitivity or life-threatening reaction following administration of diphtheria, tetanus or pertussis vaccines or to any components of the vaccine (see Section COMPOSITION – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information);

  • any encephalopathy with unknown aetiology such as coma, prolonged seizures, or decreased level of consciousness within 7 days following previous vaccination with any whooping cough vaccine;

  • progressive or unstable neurological disorders, uncontrolled epilepsy or progressive encephalopathy.